Arkana Advances is a research podcast, hosted by Dr. Rebecca May, discussing the work of Arkana physicians and scientists as they ask questions that lead to advancing the understanding of disease.
All content for Arkana Advances is the property of Arkana Laboratories and is served directly from their servers
with no modification, redirects, or rehosting. The podcast is not affiliated with or endorsed by Podjoint in any way.
Arkana Advances is a research podcast, hosted by Dr. Rebecca May, discussing the work of Arkana physicians and scientists as they ask questions that lead to advancing the understanding of disease.
NELL1 Is A Target Antigen In Malignancy-Associated Membranous Nephropathy
Arkana Advances
19 minutes 43 seconds
3 years ago
NELL1 Is A Target Antigen In Malignancy-Associated Membranous Nephropathy
Membranous nephropathy is a leading cause of nephrotic syndrome. On renal biopsy, immunofluorescence shows granular capillary loop deposits, and holes are seen in the capillary loops on silver stain. Electron microscopy shows subepithelial immune complex deposits. A majority of cases have autoantibodies against PLA2R and THSD7A. This study identified a new target antigen, NELL1, which was present in 1.7% of membranous cases. NELL1 can also be detected in the serum of these patients. Approximately 33% of patients with NELL1 have a known malignancy. Patients with successful treatment of the malignancy showed good responses to membranous treatment. Patients with NELL1 positive membranous nephropathy should receive age-appropriate cancer screening.
Read the paper: https://www.kidney-international.org/action/showPdf?pii=S0085-2538%2820%2930956-X
[embed]https://www.youtube.com/watch?v=WdMk3gAo7mc[/embed]
Arkana Advances
Arkana Advances is a research podcast, hosted by Dr. Rebecca May, discussing the work of Arkana physicians and scientists as they ask questions that lead to advancing the understanding of disease.
